First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
Saved in:
| Title: | First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. |
|---|---|
| Authors: | Paz-Ares LG; Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Clinical Research Unit, Universidad Complutense & CiberOnc, Madrid, Spain. Electronic address: lpazaresr@seom.org., Ramalingam SS; Winship Cancer Institute, Emory University, Atlanta, Georgia., Ciuleanu TE; Institutul Oncologic Prof Dr Ion Chiricuta and UMF Iuliu Hatieganu, Cluj Napoca, România., Lee JS; Seoul National University Bundang Hospital, Seongnam, Republic of Korea., Urban L; Matrai Gyogyintezet, Matrahaza, Hungary., Caro RB; Hospital Universitario Virgen Del Rocio, Instituto de Biomedicina de Seville, Seville, Spain., Park K; Samsung Medical Center at Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Sakai H; Saitama Cancer Center, Saitama, Japan., Ohe Y; National Cancer Center Hospital, Tokyo, Japan., Nishio M; Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Audigier-Valette C; Hôpital Sainte Musse, Toulon, France., Burgers JA; Netherlands Cancer Institute, Amsterdam, The Netherlands., Pluzanski A; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Sangha R; Cross Cancer Institute, Edmonton, Alberta, Canada., Gallardo C; Fundacion Arturo Lopez Perez, Santiago, Chile., Takeda M; Kindai University Faculty of Medicine, Osaka, Japan., Linardou H; Metropolitan Hospital, Neo Faliro, Greece., Lupinacci L; Hospital Italiano De Buenos Aires, Buenos Aires, Argentina., Lee KH; Chungbuk National University Hospital, Cheongju-si, Republic of Korea., Caserta C; Santa Maria Hospital, Terni, Italy., Provencio M; Hosp. Univ. Puerta De Hierro-IDIPHIM, Universidad Autónoma de Madrid, Madrid, Spain., Carcereny E; Catalan Institute of Oncology-Germans Trias i Pujol Hospital, B-ARGO group, Badalona, Spain., Otterson GA; The Ohio State University, Columbus, Ohio., Schenker M; SF. Nectarie Oncology Center, Craiova, Romania., Zurawski B; Ambulatorium Chemioterapii, Bydgoszcz, Poland., Alexandru A; Institute of Oncology 'Prof. Dr. Alexandru Trestioreanu' Bucha, Bucharest, Romania., Vergnenegre A; Limoges University Hospital, Limoges, France., Raimbourg J; ICO Rene Gauducheau, St Herblain, France., Feeney K; St John of God Hospital Murdoch, Perth, Australia., Kim SW; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Borghaei H; Fox Chase Cancer Center, Philadelphia, Pennsylvania., O'Byrne KJ; Queensland University of Technology, Princess Alexandra Hospital, Brisbane, Australia., Hellmann MD; Memorial Sloan Kettering Cancer Center, New York, New York., Memaj A; Bristol Myers Squibb, Princeton, New Jersey., Nathan FE; Bristol Myers Squibb, Princeton, New Jersey., Bushong J; Bristol Myers Squibb, Princeton, New Jersey., Tran P; Bristol Myers Squibb, Princeton, New Jersey., Brahmer JR; Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland., Reck M; Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany. |
| Source: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2022 Feb; Vol. 17 (2), pp. 289-308. Date of Electronic Publication: 2021 Oct 12. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
